Paras Biopharmaceuticals Finland Oy sell "Anakinra Biosimilar Candidate"

Paras Biopharmaceuticals has been steadily advancing an Anakinra/IL-1RA biosimilar (referencing Kineret™), with growing progress toward realizing the asset's value; a few points may be of interest. Kineret™ (originator: Sobi) is indicated to reduce signs, symptoms, and joint damage progression in moderate-to-severe active rheumatoid arthritis in adults 18 and older; to treat Neonatal-Onset Multisystem Inflammatory Disease (NOMID), a form of Cryopyrin-Associated Periodic Syndrome (CAPS); and to treat Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Paras Biopharmaceuticals has invested extensively in Anakinra development, generating substantial proprietary data; since the molecule is off-patent, remaining costs for further development and regulatory approval are limited.